Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report

Overview

Journal Integr Med (Encinitas)

Date 2025 Feb 3

PMID 39896831

Authors

Leah Linder

Affiliations

Soon will be listed here.

Abstract

This case report presents a 46-year-old woman with type 2 diabetes mellitus (T2DM) who sought to discontinue glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) therapy while maintaining her weight and metabolic health. Her desire to reduce medication dependency, combined with her apprehension about potential metabolic regression following discontinuation of the drug, highlights a challenge often faced by patients managing chronic conditions, and the value of naturopathic adjunctive therapies to support these individuals in their wellness goals. This report details a comprehensive intervention strategy combining probiotics, nutrient supplementation, and lifestyle modifications to address her concerns. Over an 8-week period post-GLP-1 RAs therapy discontinuation, she maintained weight loss, improved glycemic control and lipid profile, demonstrated improvements in micronutrient levels, and experienced improvements in her quality of life. This case contributes to the growing body of evidence suggesting that targeted naturopathic interventions can play a supportive role in managing T2DM and mitigating the reliance on pharmacotherapy without compromising health outcomes.

References

Turpin T, Thouvenot K, Gonthier M . Adipokines and Bacterial Metabolites: A Pivotal Molecular Bridge Linking Obesity and Gut Microbiota Dysbiosis to Target. Biomolecules. 2023; 13(12). PMC: 10742113. DOI: 10.3390/biom13121692. View

Priyadarshini M, Lednovich K, Xu K, Gough S, Wicksteed B, Layden B . FFAR from the Gut Microbiome Crowd: SCFA Receptors in T1D Pathology. Metabolites. 2021; 11(5). PMC: 8151283. DOI: 10.3390/metabo11050302. View

Shi Q, Nong K, Vandvik P, Guyatt G, Schnell O, Ryden L . Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023; 381:e074068. PMC: 10077111. DOI: 10.1136/bmj-2022-074068. View

Mehdi S, Pusapati S, Anwar M, Lohana D, Kumar P, Nandula S . Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023; 14:1148209. PMC: 10230051. DOI: 10.3389/fimmu.2023.1148209. View

Patra D, Banerjee D, Ramprasad P, Roy S, Pal D, Dasgupta S . Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes. Front Mol Biosci. 2023; 10:1224982. PMC: 10575740. DOI: 10.3389/fmolb.2023.1224982. View

Rad E, Djalali M, Koohdani F, Saboor-Yaraghi A, Eshraghian M, Hassan Javanbakht M . The Effects of Vitamin D Supplementation on Glucose Control and Insulin Resistance in Patients with Diabetes Type 2: A Randomized Clinical Trial Study. Iran J Public Health. 2015; 43(12):1651-6. PMC: 4499086. View

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe K . Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020; 21(17). PMC: 7503727. DOI: 10.3390/ijms21176275. View

Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C . Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. Aging Dis. 2022; 13(4):1106-1126. PMC: 9286904. DOI: 10.14336/AD.2022.0104. View

Cox T, Lundgren P, Nath K, Thaiss C . Metabolic control by the microbiome. Genome Med. 2022; 14(1):80. PMC: 9338551. DOI: 10.1186/s13073-022-01092-0. View

10.

Iatcu C, Steen A, Covasa M . Gut Microbiota and Complications of Type-2 Diabetes. Nutrients. 2022; 14(1). PMC: 8747253. DOI: 10.3390/nu14010166. View

11.

Shami D, Sousou J, Batarseh E, Alazrai L . The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes. Cureus. 2023; 15(1):e33484. PMC: 9901266. DOI: 10.7759/cureus.33484. View

12.

Agus A, Planchais J, Sokol H . Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018; 23(6):716-724. DOI: 10.1016/j.chom.2018.05.003. View

13.

Hinnen D . Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr. 2017; 30(3):202-210. PMC: 5556578. DOI: 10.2337/ds16-0026. View

14.

Tolhurst G, Heffron H, Lam Y, Parker H, Habib A, Diakogiannaki E . Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2011; 61(2):364-71. PMC: 3266401. DOI: 10.2337/db11-1019. View

15.

Marsico F, Paolillo S, Gargiulo P, Bruzzese D, DellAversana S, Esposito I . Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020; 41(35):3346-3358. DOI: 10.1093/eurheartj/ehaa082. View

16.

Farahmand M, Daneshzad E, Fung T, Zahidi F, Muhammadi M, Bellissimo N . What is the impact of vitamin D supplementation on glycemic control in people with type-2 diabetes: a systematic review and meta-analysis of randomized controlled trails. BMC Endocr Disord. 2023; 23(1):15. PMC: 9841647. DOI: 10.1186/s12902-022-01209-x. View

17.

Chimerel C, Emery E, Summers D, Keyser U, Gribble F, Reimann F . Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 2014; 9(4):1202-8. PMC: 4308618. DOI: 10.1016/j.celrep.2014.10.032. View

18.

Borror A, Zieff G, Battaglini C, Stoner L . The Effects of Postprandial Exercise on Glucose Control in Individuals with Type 2 Diabetes: A Systematic Review. Sports Med. 2018; 48(6):1479-1491. DOI: 10.1007/s40279-018-0864-x. View

19.

Batulwar P, Anjankar A . Individuals Diagnosed With Type 2 Diabetes Mellitus and the Status of Vitamin B12 Deficiency: A Review. Cureus. 2024; 16(2):e55103. PMC: 10978817. DOI: 10.7759/cureus.55103. View

20.

Tripathi A, Debelius J, Brenner D, Karin M, Loomba R, Schnabl B . The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018; 15(7):397-411. PMC: 6319369. DOI: 10.1038/s41575-018-0011-z. View